Clinical Research Directory

This study is seeking participants who should meet the usual prescribing criteria for Cibinqo® Tablets as per the Local Product Document (LPD) and should be entered into the study at the physician's discretion. Inclusion Criteria: 1. Patients with moderate to severe AD who have been determined to start treatment with Cibinqo Tablet according to the approved indications of the medicinal product. • Atopic Dermatitis Cibinqo Tablet is indicated for the treatment of patients 12 years of age and older with moderate-to-severe atopic dermatitis who have required systemic therapies. 2. Evidence of a personally signed and dated informed consent document indicating that the patient or their parent(s)/legal guardian, if applicable, have been informed of all pertinent aspects of the study Exclusion Criteria: 1. Patients who have previously received Cibinqo Tablet 2. Patients concurrently participating in other studies involving therapeutic interventions and/or investigational products 3. Patients who have contraindications to Cibinqo Tablet as specified in the approved LPD • Contraindications to Cibinqo Tablet * Patients with platelet count \<150 × 103/mm3, an absolute neutrophil count (ANC) \<1 × 103/mm3, an absolute lymphocyte count (ALC) \<0.5 × 103/mm3 or who have a haemoglobin value \<8 g/dL * Hypersensitivity to the active substance or to any of the excipients * Active serious systemic infetions, including tuberculosis(TB) * Severe hepatic impairment * Pregnancy and breast-feeding * Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption